Glycated albumin (GA) is emerging as an alternative marker to glycated haemoglobin (HbA1c) for monitoring glycemic control, proving particularly useful in clinical settings where HbA1c loses reliability, such as in haemoglobinopathies, diabetic nephropathy, and during pregnancy. This review explores the established clinical applications and future perspectives of GA, providing insights for its potential integration into endocrinology practice.
Albumina glicata: nuovo parametro di controllo glicemico nella pratica endocrinologica [Glycated albumin: a new glycemic control parameter in endocrinological practice]
Gianluca Marzi
Primo
;Martina VerrientiSecondo
;Maria Chiara ZatelliPenultimo
;Maria Rosaria AmbrosioUltimo
2026
Abstract
Glycated albumin (GA) is emerging as an alternative marker to glycated haemoglobin (HbA1c) for monitoring glycemic control, proving particularly useful in clinical settings where HbA1c loses reliability, such as in haemoglobinopathies, diabetic nephropathy, and during pregnancy. This review explores the established clinical applications and future perspectives of GA, providing insights for its potential integration into endocrinology practice.File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
Marzi et al Albumina Glicata.pdf
solo gestori archivio
Tipologia:
Full text (versione editoriale)
Licenza:
NON PUBBLICO - Accesso privato/ristretto
Dimensione
1.01 MB
Formato
Adobe PDF
|
1.01 MB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in SFERA sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
